drugset / Trial / NCT03614949
SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer
Phase 2
Active not recruiting
21 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if treatment with atezolizumab and stereotactic body radiation therapy (SBRT) will improve the objective response rate (ORR) compared with atezolizumab alone in patients with recurrent, persistent, or metastatic cervical cancer.
Timeline
- Start
- 2019-01-29
- Primary completion
- 2028-10
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |